Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021.
1. Could you tell us a little about trastuzumab deruxtecan and its potential advantages over other trastuzumab antibody-drug conjugates? 00:20-01:49
2. What are the objectives of the DEBBRAH Phase II study? 01:49-02:55
3. Could you tell us a little about the study cohorts and eligibility criteria of the study? 02:55-03:58
4. What have been the preliminary findings of the study? 03:58-06:33
5. Where do you expect trastuzumab deruxtecan to sit in the treatment paradigm for HER2+ or HER2-low-expressing advanced breast cancer? 06:33-08:40
Speaker Disclosure: Marta Vaz Batista discloses honoraria from Daiichi Sankyo.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the San Antonio Breast Cancer Symposium 2021
Share this Video
Related Videos In Breast Cancer
Lynsey Drewett, AACR 2022: Olaparib in Combination With Neoadjuvant Platinum-based Chemotherapy – the PARTNER Study
It was a pleasure to speak with Dr Lynsey Drewett (University of Cambridge, Cambridge, UK) around the PARTNER study, investigating the efficacy and safety of the addition of olaparib to neoadjuvant platinum-based chemotherapy in the treatment of basal TNBC and/or gBRCA breast cancer. The abstract ‘PARTNER: Randomised, phase II/III trial to evaluate the safety and […]
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!